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Abstract
Background
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an
inherited cardiomyopathy mainly caused by desmosomal gene mutation. More
than half of Caucasian probands have desmosomal mutations, which lead to
earlier onset of ventricular arrhythmias. Among non-Caucasians, the genetic
background of ARVD/C probands and its prognostic impact remain unclear.
Methods and Results
We genotyped 99 unrelated Japanese ARVD/C probands for plakophilin 2
(PKP2), desmoglein 2 (DSG2), desmoplakin (DSP), and desmocollin 2 (DSC2)
between 2005 and 2014. Seventy-five probands who fulfilled “definite” category
according to the 2010 Task Force Criteria (TFC) were enrolled and followed up
for 6.4 years. Sixty-four percent of probands had desmosomal mutations; DSG2
was predominant (48% of mutations) followed by PKP2 (38%). DSG2 mutations
were almost missense, whereas over 90% of PKP2 mutations were truncating
mutations. Lethal ventricular arrhythmias (VAs, sustained ventricular tachycar-
dia/fibrillation) occurred in 57% of probands as the first manifestation and 71%
at the end of follow-up. Five died during follow-up. Truncating mutation carriers
exhibited earlier lethal VAs onset compared to missense mutation carriers or
mutation negatives (age at onset 35  12, 49  16, and 50  19 years, respec-
tively, P < 0.05 in each). Cox proportional hazard analysis revealed for the first
time that, compared to mutation negatives, truncating mutation carriers had
higher risk for lethal VAs, and especially for onset by their 40s, in an age-depen-
dent manner (RR = 4.6, P < 0.01 by their 40s; RR = 2.9, P = 0.01 by their 50s).
Conclusion
The genetic background of Japanese ARVD/C probands is distinct from that of
Caucasian probands, leading to distinct prognosis. The most affected gene muta-
tions in Japanese probands were missense mutations in DSG2 leading to modest
outcome, whereas PKP2 truncating mutations were the second most and might
be a strong marker for lethal VAs in non-Caucasian Japanese ARVD/C probands.
Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopa-
thy (ARVD/C) is an inherited cardiomyopathy character-
ized by right ventricular structural impairment and
electrophysiological disturbance, both attributed
histologically to cellular loss and succeeding fibro-fatty
displacement of myocytes (Thiene 2015). ARVD/C is pro-
gressive after its onset, which can occur as early as the
teen years, though molecular degradation can begin even
earlier in life (Pilichou et al. 2009). Desmosomal gene
mutations play a key role as triggers of disease
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development (Sen-Chowdhry et al. 2005; Groeneweg et al.
2015) and have been identified in over half of Caucasian
probands (Basso et al. 2012). Plakophilin 2 (PKP2,OMIM
reference number*602861) mutations are significantly
predominant in Caucasian (Groeneweg et al. 2015) and
some Chinese probands (Bao et al. 2013; Zhou et al.
2015). In the previous report from our group, PKP2
mutations were the most common among 29 probands
with definite ARVD/C phenotype in a preliminary genetic
study for Japanese (Ohno et al. 2013), although muta-
tions were to be more sharply distinguished from vari-
ants. Regarding genetic background of non-Caucasian
ARVD/C patients and family members, its associated clin-
ical phenotypes and outcomes have not yet been fully
defined. In this study, we sought to examine the genetic
background, phenotype and phenotype variation, and
outcomes of mono-racial non-Caucasian Japanese ARVD/
C probands over the long term.
Methods
Study population
This study was conducted as part of a comprehensive
nationwide survey of inherited arrhythmias in Japan.
Ninety-nine unrelated Japanese probands suspected to
have ARVD/C and 74 of their family members were geno-
typed between 2005 and 2014. Of the 99 consecutive pro-
bands, 75 who fulfilled the “definite” category according
to the 2010 Task Force Criteria (TFC) (Marcus et al.
2010) were enrolled. Briefly, “definite” category was deter-
mined if proband sufficed any of two major, one major
plus two minor, or four minor criteria in different pheno-
typic criteria as follows; “right ventricular structural alter-
ations,” “tissue characterization in cardiac biopsy
sample,” “repolarization abnormalities in electrocardio-
gram (ECG),” “depolarization abnormalities in ECG,”
“arrhythmias,” and “family history” as commonly
applied.
Of the 74 family members, 58 were enrolled whose
proband relatives had met the 2010 TFC. All probands
and family members gave written informed consent for
both genetic testing and the research survey prior to
genotyping. This study protocol was approved by the
ethics committee of Shiga University of Medical Science
(25-167).
Phenotype assessment
Each proband’s ARVD/C diagnosis was reviewed by two
cardiologists at different time points. First, one cardiolo-
gist examined each index proband and his or her family
members, recording medical information including ECG,
signal-averaged electrocardiogram, echocardiogram, car-
diac magnetic resonance imaging or right ventriculogra-
phy, and Holter recording (“first evaluation”). The
proband was then referred to the genetic laboratory. At
this point a second cardiologist reviewed the original
records and survey forms regarding the clinical diagnosis.
Genotyping was performed and the proband was enrolled
in the study (“genotyping and study enroll”). Finally, the
initial cardiologist followed up with all probands and
conducted a follow-up survey (“final evaluation”).
To determine genotype–phenotype correlations, the
odds for mutation-positive status were derived from
logistic analysis, performed as previously described (Te
Riele et al. 2016), of all probands with “possible” TFC
phenotype (i.e., with one major or two minor criteria in
different phenotypic criteria as described above) or a
more severe phenotype. We employed “the modified
TFC” which are mutation-independent and affected only
by clinical phenotype. Probands with “possible” pheno-
type according to the 2010 TFC are supposed to be
upgraded into the “definite” category by the presence of a
pathogenic mutation, as this constitutes one additional
major criterion. In the genotype–phenotype analysis, we
employed the following indices in addition to the 2010
TFC: right ventricular fragmentation as observed in the
form of fragmented QRS in V1-3 leads in ECG was
defined as depolarization anomaly; reduced left ventricu-
lar ejection fraction (LVEF) <50% as left ventricular dys-
function; J wave in two or more serial leads in either the
anterior, inferior, or lateral leads in ECG. In phenotype
progression analysis, each phenotype was quantified as
follows: 2 points for a major anomaly, 1 point for
a minor anomaly. A “definite” phenotype was defined as
a score of 4 or more points, “borderline” as a 3-point
score, and “possible” as a 2-point score.
Genetic analysis
Genomic deoxyribonucleic acid (DNA) was isolated from
venous blood lymphocytes as previously described (Ohno
et al. 2013). Genotyping was performed according to a
bidirectional direct DNA sequencing method targeting a
comprehensive open reading frame/splice site mutational
analysis of four major ARVD/C susceptibility genes: PKP2
(OMIM reference number*602861), encoding plakophilin
2; DSP (*125647), encoding desmoplakin; DSG2
(*125671), encoding desmoglein 2; and DSC2 (*125645),
encoding desmocollin 2. To screen for nondesmosomal
genes, all probands were genotyped for LMNA (*150330)
and SCN5A (*600163), encoding lamin A/C and voltage
gated sodium channel alpha subunit type V, respectively.
Two probands carrying the LMNA mutation and their
four relatives, all previously reported by our laboratory
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(Kato et al. 2015), and three probands carrying the
SCN5A mutation either alone or in combination with
desmosomal mutations and their eight relatives were
excluded from this study. The coding DNA sequences of
PKP2, DSP, DSG2, DSC2, LMNA, and SCN5A were based
on the GenBank reference sequences; NM_004572.3, NM_
001008844.2, NM_001943.4, NM_004949.4, NM_
001257374.2, and NM_00335.4, respectively. Genetic
screening of family members was focused on the anoma-
lous gene(s) found in their respective probands.
To determine whether a repetitively identified variant
p.Asp494Ala in DSG2 is a recurrent or has a common
founder, both repeat numbers of a microsatellite 15xGT
located at ch18:31499358-87 was analyzed using primers
50-GAGATTGTGCCACTGCACTC-30 and 50-CGAC-
CACGGTAGGAATTCTG-30.
Variant interpretation
Variants were heterozygotes if not specified as homozy-
gotes. All null variants including nonsense, frameshift,
canonical 1 or 2 splice sites, or single/multiple exon
deletion/duplication were considered pathogenic. Inter-
pretation for missense variants is detailed in Appendix S1.
Increased odds ratio (>5.0 as compared to Japanese con-
trols) was considered as sufficient evidence of pathogenic-
ity if there was a discrepancy in minor allele frequency
(MAF) between probands and controls according to the
latest guidelines for the interpretation of the variants
(Richards et al. 2015). In that context, the variant
p.Asp494Ala in DSG2 (DSG2-D494A) is a single exception
that has been identified in the higher odds ratio (=26.9)
for definitive ARVD/C. On the basis of its slightly higher
MAF (0.006) in Japanese controls and the lack of con-
vincing data that demonstrates its pathogenicity, we
regarded this common variant as the variant of uncertain
significance when identified as heterozygote. Homozygous
mutation was regarded as pathogenic unless the available
databases listed the index variant as a homozygote. For
further analyses, pathogenic mutations were subclassified
as either truncating mutation synonymous with the null
variant or nontruncating mutation which indicated mis-
sense mutation. Multiple missense mutations included
compound heterozygotes (trans-), monogenic double
mutations (cis-), and homozygous mutations; the number
of mutations harbored in each proband was also analyzed
for comparison to previous report (Rigato et al. 2013).
Follow-up, outcome, and reevaluation
All probands and family members received a follow-up by
the initial cardiologist after genotyping. The phenotype
and clinical course as of the date of that follow-up were
reported in detail to the second cardiologist (Genetic
Testing Laboratory, Shiga University of Medical Science)
via a survey form. The most recent survey forms were
collected in September 2015. The endpoints thus identi-
fied were spontaneous lethal ventricular arrhythmias
(VAs) including sudden cardiac death (SCD), resuscitated
cardiopulmonary arrest (CPA), sustained ventricular
tachycardia (VT), ventricular fibrillation (VF), and appro-
priate cardioversion by implantable cardioverter defibrilla-
tor (ICD) or cardiac resynchronization therapy with
defibrillator (CRT-D). Antitachycardia pacing therapy by
ICD or CRT-D was not included among the lethal events
because it was sometimes set to fire against nonsustained
VT.
Statistics
Continuous variables were presented as means  SD.
Comparison between two or three groups was made by
Student’s t-test or the Kruskal–Wallis test, respectively.
Categorical variables were expressed as frequency (%)
with absolute numbers and compared by the chi-square
test or the Mann–Whitney U test between two or three
groups, respectively. For outcome analyses, patients were
divided into groups based on mutation status. Kaplan–
Meier survival curves were constructed by plotting age at
onset. A two-tailed probability (P) value <0.05 was
accepted as significant. A software package (JMP 9.0; SAS
Institute Inc., Cary, NC, USA) was used for statistical
analysis.
Results
Phenotype of Japanese ARVD/C probands
Clinical diagnoses at the time of genotyping and disease
progression are illustrated in Figure 1. Phenotype pro-
gressed during the study period in three probands; this
occurred prior to genotyping in two probands and after
genotyping in another one. The baseline clinical charac-
teristics of the 75 probands at genotyping are shown in
Table 1. The most common initial manifestation was
lethal VAs (43 probands, 57%) followed by nonlethal VAs
(12, 16%) and syncope (9, 12%). Of the 43 probands
with previous lethal VAs before genotyping, three had
been successfully rescued from CPA, whereas the remain-
ing 40 had sustained VT as the initial manifestation. Prior
hospitalization for heart failure was less common as the
first symptom in this cohort. ICDs were implanted in
total of 41 probands, 33 before and eight after genotyp-
ing. Family history of SCD in a first-degree relative was
reported by four of 75 probands; the same condition in a
second-degree relative was reported by seven.
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Phenotypes of family members of probands
in Japanese ARVD/C cohort
Fifty-eight relatives from 26 families were genotyped at a
mean age of 40  21 years. Six (10%), one (2%), and 44
(76%) relatives met the criteria for ARVD/C in the defi-
nite, borderline, and possible categories, respectively.
Three individuals had experienced lethal VAs prior to
genotyping, one had a history of unexplained syncope,
and two had shown asymptomatic frequent premature
Figure 1. Time course of diagnoses and
phenotype alteration during follow-up. Note
that diagnoses rarely changed during the mean
follow-up period of 6.4 years. “Definite,”
“borderline,” and “possible” are defined as by
the 2010 TFC. “Unlikely” means that the
subject did not meet enough of the criteria to
be sorted into the “possible” category.
Table 1. Clinical characteristics of 75 probands who fulfilled the 2010 Task Force Criteria.
Total N = 75 Mutation (+) N = 48 Mutation () N = 27 P value
Age at first evaluation, yrs 44  18 42  18 49  18 0.08
Age at genotyping, yrs 49  18 47  18 52  18 0.17
Age at final evaluation, yrs 50  18 49  18 54  19 0.24
Follow-up period, yrs 6.4  6.2 7.2  6.7 4.6  4.8 0.08
Male, n (%) 55 (73) 35 (71) 20 (77) 0.61
SCD in 1st degree relative 4 (5) 3 (6) 1 (4) 0.66
SCD in 2nd degree relative 7 (9) 5 (10) 2 (7) 0.70
First manifestation
Lethal VAs, n (%) 43 (57) 29 (60) 14 (52) 0.67
Nonlethal VAs, n (%) 12 (16) 7 (15) 5 (19) 0.58
Heart failure, n (%) 5 (7) 4 (8) 1 (4) 0.48
Family history of SCD, n (%) 2 (3) 2 (4) 0 0.30
Syncope, n (%) 9 (12) 5 (10) 4 (15) 0.51
Others, (%) 3 (4) 1 (2) 2 (8) 0.23
Major structural anomaly, (%) 51 (68) 32 (65) 19 (70) 0.49
Major repolarization anomaly, n (%) 47 (63) 35 (73) 12 (44) 0.03
Major depolarization anomaly, n (%) 29 (39) 17 (35) 12 (44) 0.33
Major ARVD/C-related VAs, n (%) 18 (24) 10 (21) 8 (30) 0.31
Phenotype score at genotyping, pts 5.2  1.7 5.2  1.6 5.2  1.8 0.65
LVDD, mm 47  7 48  7 47  6 0.59
LVDS, mm 33  7 33  8 33  5 0.82
LVEF, % 53  15 51  16 55  12 0.41
ICD implantation at final evaluation, n (%) 41 (55) 24 (50) 10 (37) 0.38
Phenotype score at final evaluation, pts 5.4  1.9 5.4  1.8 5.2  2.0 0.53
Values are means  SD or n/N (%). SCD, sudden cardiac death; VAs, ventricular arrhythmias; NA, not applicable; LVDD, left ventricular end-dia-
stolic dimension; LVDS, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter defibrillator.
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ventricular contractions on Holter recordings. The
remaining 52 relatives were genotyped for the purpose of
family screening in the absence of any ARVD/C-related
symptoms.
Genotypes of Japanese ARVD/C probands
and family members
Table 2 details identified mutations in bold, variants in
plain italic, reference SNP ID, previous reports, MAF in
Japanese controls, the number of carriers in the present
cohort, and in silico prediction of protein changes. In 48
(64%) of the 75 probands, 30 pathogenic mutations were
identified including seven premature stop-gained (in
seven probands), four frameshifts (in 11), two splice site
mutations (in two), one multi-exon deletion (in one)
(Sonoda et al. 2017), and 16 missense mutations (in 30)
(see details in Table 2 and Table S1). Of the 16 missense
mutations, one (DSG2-p.Arg46Trp) had previously been
reported in a Caucasian ARVD/C cohort (Gehmlich et al.
2012; Groeneweg et al. 2015), nine had previously been
reported by our group (Ohno et al. 2013), and six were
novel. Of particular note, as described in Figure 2A, the
most commonly affected genetic locus in Japanese ARVD/
C probands was DSG2 (10 mutations in 25 probands;
monogenic in 23 probands and digenic in two probands)
followed by PKP2 (12 mutations in 19 probands; mono-
genic in 18 probands and digenic in one proband). Muta-
tions in DSP (five mutations in five probands; monogenic
in two probands and digenic in three probands) and
DSC2 (two double missense mutations in one and one
frameshift in one) were far less common. Figure 2B
demonstrates the contrasting distribution of missense and
truncating mutation in PKP2 and DSG2. Plakophilin 2
mutations were specifically dominated by truncating
mutations, which accounted for 18 of 19 affected pro-
bands including digenic with desmoplakin mutation.
Multiple mutations were identified mainly in DSG2 as
shown in Table S1.
Of the 58 family members, 21 had inherited pathogenic
mutations, including two truncating mutations (either of
which was found in five relatives). Table 2 listed muta-
tions harbored among family members along with their
proband relatives.
Regarding the most common variant p.Asp494Ala in
DSG2, as shown in Table S2, linkage analysis revealed the
fully same microsatellite pattern in one allele, and less
divergent patterns in another allele among 18 probands
with p.Asp494Ala in DSG2. In combination with the
genealogical independency of probands, p.Asp494Ala vari-
ant in DSG2 is thought for the first time to have a com-
mon founder.
Outcomes of Japanese ARVD/C probands
During 6.4  6.2 years of follow-up after genotyping,
recurrent lethal VAs occurred in 10 of the 43 probands
who had histories of lethal VAs prior to genotyping,
whereas de novo events developed in another 10 probands.
A total of 53 (71%) probands exhibited lethal VAs at an
average age of 45  17 years. Five probands (6.4%) died
during the follow-up period, two from end-stage heart fail-
ure (HF) at a mean age of 53 years and three from SCD at
a mean age of 56 years. Lethal VAs occurred earlier in
truncating mutation carriers than in either mutation nega-
tives (35  12 vs. 50  19 years, P < 0.05) or nontruncat-
ing mutation carriers (35  12 vs. 49  16, P < 0.05).
Kaplan–Meier estimation for lethal VAs (Fig. 3A) did
not show survival differences among each mutation sta-
tus. Appropriate ICD or CRT-D interventions for lethal
VAs were administered in eight of 41 probands at an
average of 5.8  5.3 (0–13.3) years after ICD or CRT-D
implantation, mainly among candidates for secondary
prevention (seven of eight probands). The appropriate
ICD intervention rate during the mean follow-up period
of 4.85 years after implantation was 9.57%/year.
Outcomes in family members of Japanese
ARVD/C probands
Though probands had a higher incidence of life-threaten-
ing events, their family members rarely developed ARVD/
C-related symptoms. Three relatives had experienced
lethal VAs prior to genotyping; all these were nontruncat-
ing mutation carriers (DSG2-R292C in two, and multiple
mutations of DSG2-R292C along with DSG2-R46W in
one). One relative with a truncating mutation (PKP2-
R577Dfs) developed de novo appropriate antitachycardia
pacing therapy against VAs after prophylactic ICD
implantation. The remaining 54 relatives remained free
from VAs before and after genotyping.
Age- and mutation-dependent outcomes in
Japanese ARVD/C probands
Because many probands, especially mutation positives, had
early onset of manifestations, we grouped them into three
categories according to time to onset: those exhibiting
symptoms by their 30s (revealing risk at 29 years of age),
those by their 40s (revealing risk at 39 years of age), and
those by their 50s (revealing risk at 49 years of age). Fig-
ure 3B described the relative risks among different muta-
tion status compared to mutation negatives. Cox
proportional hazard analyses estimated that truncating
mutation carriers had the highest arrhythmic risk, with 2.6-
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Table 2. Desmosomal variants identified in Japanese ARVD/C cohort.
Nucleotide change
Protein change
(reference SNP ID) Previous report
MAF in controls/
covered alleles
Carriers in
Probands
(N = 75)
Carriers in
relatives‡
(N = 58)
Desmoglein 2
c.1481 a>c p.Asp494Ala (rs193298428) Ohno et al. (2013) 0.006/2204 18 (4 homozygotes) 5
c.874 c>t p.Arg292Cys Novel 0.004/2212 14 (3 homozygotes) 10
c.136 c>t p.Arg46Trp Groeneweg et al. (2015) Unreported 2 2
c.803 a>t p.Asn268Ile Novel 0.002/858 2 0
c.1562 a>g p.Asp521Gly Novel 0.002/2204 2 0
c.847g>a p.Glu283Lys Novel Unreported 1 2
c.1448g>a p.Gly483Asp Novel Unreported 1 0
c.1880-1g>t Abnormal splice product Novel Unreported 1 0
c.2681 t>g p.Leu894Trp Novel 0.001/742 1 0
c.1592 t>g p.Phe531Cys (rs200484060) Ohno et al. (2013) 0.002/858 1 1
c.2536g>a p.Asp846Asn Novel Unreported 1 0
c.2780 c>t p.Pro927Leu (rs146402368) Ohno et al. (2013) 0.017/2292 2 0
c.1597g>a p.Val533Ile (rs199761749) Novel 0.005/2218 1 0
c.3118g>a p.Val1040Ile (rs201966605) Novel Insufficient data 1 0
c.1525g>a p.Asp509Asn Novel 0.003/600 1 0
Plakophilin 2
c.1725_1728 dupGATG p.Arg577fs Ohno et al. (2013) Unreported 8 3
c.1132 c>t p.Gln378* Ohno et al. (2013);
Groeneweg et al. (2015)
Unreported 1 0
c. 795-811del p.Leu266fs Ohno et al. (2013) Unreported 1 0
c.2119 c>t p.Gln707* Ohno et al. (2013) Unreported 1 0
c.2095 c>t p.Gln699* Ohno et al. (2013) Unreported 1 0
c. 1368-1369insA p.Gln456fs Sonoda et al. (2017) Unreported 1 0
c.2203 c>t p.Arg735* Novel† Unreported 1 0
c.1035-1g>a Abnormal splice product Novel Unreported 1 0
Deletion exons 1-14 Groeneweg et al. (2015);
Sonoda et al. (2017)
Unreported 1 0
c.1951 c>t p.Arg651* Bao et al. (2013) Unreported 1 0
c.1969g>t p.Glu657* Novel Unreported 1 0
c.976g>a p.Ala326Thr (homozygote)
rs148480056
Ohno et al. (2013) Unreported as
homozygote
1 0
c.2150 c>t p.Pro717Leu
rs144018320
Ohno et al. (2013) 0.011/2202 6 0
c.953A>C p.His318Pro
rs181098323
Ohno et al. (2013) Unreported 4 0
*39 a>g Novel Unreported 1 0
Desmoplakin
c.8269g>c p.Asp2757His Ohno et al. (2013) Insufficient data 1 0
c.4741 a>g p.Lys1581Glu (homozygote)
rs186842903
Ohno et al. (2013) Unreported as
homozygote
1 0
c.1203g>t p.Lys401Asn Ohno et al. (2013) Unreported 1 1
c.593 a>c p.Gln198Pro (homozygote) Ohno et al. (2013) Unreported as
homozygote
1 0
c.4198 c>t p.Arg1400* Bao et al. (2013) Unreported 1 2
c.2360 a>g p.Try787Cys Ohno et al. (2013) 0.005/1066 1 0
c.8455 a>c p.Met2819Leu
rs138329459
Ohno et al. (2013) 0.002/598 1 0
c.6505 c>g p.Gln2169Glu Novel Unreported 1 0
(Continued)
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(P = N.S.), 4.6-(P < 0.01), and 2.9-(P = 0.01) fold higher
by their 30s, 40s, and 50s, respectively, compared to muta-
tion negatives. Nontruncating mutation carriers showed
similar trends in the age of onset with mutation negatives.
As the results above, age-dependent difference in
arrhythmic risk could be due to the acquisition over time
of additional conditions other than mutation status such
as physical stress. Although the incidence of lethal VAs
was lower in the teen ages (<20 years), physical activity
appeared most associated with occurrence of VAs
(Fig. 4A). At variance with previous reports in Cau-
casians, survival analysis focusing on the number of
mutations (Fig. 4B) showed no positive correlation
between the number of mutations and adverse outcomes.
Genotype–phenotype correlation in
Japanese ARVC probands
Table 3 shows the clinical characteristics associated with
different mutation statuses: (1) truncating and (2) non-
truncating mutation carriers, and (3) mutation negatives.
Repolarization anomaly was the most probable sign of
mutation-positive status (P < 0.01, Table 3). Reduced
LVEF was more frequently observed in nontruncating
mutation carriers than in truncating mutation carriers or
mutation negatives (LVEF was reduced to 46%, 58%, and
55%, respectively). The same result was found in a differ-
ent population of 88 probands selected based on “the
modified TFC” (see details in Table S3). According to
logistic regression analysis, as described in Figure S1, pos-
itive mutation status was closely associated with major
repolarization anomaly (OR = 3.52, P = 0.005) and
T-wave inversion in inferior leads (OR = 3.18, P = 0.01).
In particular, T-wave inversion over V3-4 strongly sug-
gested that a proband was a mutation carrier (OR = 4.08,
P = 0.002).
Figure 5A shows phenotype scores calculated as
described in the method section as bar graphs in three
different mutation statuses. Among truncating mutation
carriers (to the left two bars), phenotype scores were not
different irrespective of VAs (5.4 vs. 6.0 points, respec-
tively, P = N.S.). In contrast, among mutation negatives
and nontruncating mutation carriers, VAs victims showed
more severe phenotype scores (6.3 vs. 4.2 points, P = 0.07
among nontruncating mutation carriers; 6.0 vs. 3.2
points, P < 0.05 among mutation negatives).
Phenotype alteration in probands during
follow-up
In Figure 5B, phenotype scores at the study entry are
plotted against those at the time of final evaluation (mean
follow-up of 6.4  6.2 years). Red circles indicate
patients with truncating mutations, blue triangles those
with nontruncating mutations, and gray diamonds those
without mutations. Patients with <4 points, who are
therefore less likely to have ARVD/C, are shown in the
shaded area. Phenotype progression appeared to be com-
mon in each mutation status. To note, the normalization
of phenotype scores was never seen in the truncating
mutation carriers.
Discussion
Major findings from the Japanese ARVD/C
cohort
This study first detailed the genetic background of non-
Caucasian ARVD/C probands and its impact on specific
cardiac outcomes: (1) the genetic background of Japanese
ARVD/C probands is distinct from that previously
reported in Caucasian probands. DSG2 mutations were
Table 2. Continued.
Nucleotide change
Protein change
(reference SNP ID) Previous report
MAF in controls/
covered alleles
Carriers in
Probands
(N = 75)
Carriers in
relatives‡
(N = 58)
Desmocollin 2
c.394 c>t p.Arg132Cys Ohno et al. (2013) Unreported 1 0
c.607 c>t p.Arg203Cys Ohno et al. (2013) Unreported 1 1
c. 296_297 insA p.Ser99fs Novel Unreported 1 0
c.582 c>g p.Asn194Lys Ohno et al. (2013) Unreported 1 1
Bold denotes pathogenic mutation; plain italic denotes non-pathogenic variant.
†Mutated mice were produced in Cardiovascular Development and Repair Department, Centro Nacional de Investigaciones Cardiovasculares,
Madrid, Spain.
‡Mutations or variants are heterozygous in relatives.
MAF, minor allele frequency.
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predominant over those of PKP2 or other desmosomal
genes. (2) Cardiac outcome could be stratified by muta-
tion status and age. (3) Phenotypic influence on lethal
VAs was less potent in truncating mutation carriers whose
arrhythmic risk was independent of phenotype severity.
Racial disparity in genetic background
between Caucasian and non-Caucasian
Japanese ARVD/C probands
In previous reports based on large numbers of Dutch and
North-American probands (Groeneweg et al. 2015), 63%
of the Caucasian ARVD/C cohort have been mutation-
carriers. Asian probands have been uniformly scarce in
these studies although more than 5% of U.S. citizens are
of Asian descent (U. S. Census Bureau 2013). Our data
revealed that the prevalence of desmosomal mutations in
non-Caucasian, clinically conclusive, Japanese ARVD/C
probands is identical to that in Caucasians however; the
most prevalent gene mutation was DSG2. We had not
found this unique dominancy of DSG2 in the previous
report (Ohno et al. 2013) in which we had concluded
PKP2 as the most affected gene in 2013. This critical dif-
ference was brought by both the change in inclusion cri-
teria and the increase in number of enrolls. As shown in
the Table S3, mutation carriers are likely to show
advanced phenotype, and conversely, the increase in
number of probands leaded the increase in mutation car-
riers. We further employed more strict definition in
mutational interpretation than before. Two variants in
PKP2 (PKP2-P717L, PKP2-H318P) as well as one variant
in DSG2 (DSG2-P927L) had been treated as “mutation”
in the previous but they were considered as non-
pathogenic variants in the present research. Consequently,
the increase in number of probands also leaded to the
predominance of DSG2 mutations.
Surprisingly, Chinese ARVD/C probands showed higher
prevalence of PKP2 mutations than other desmosomal
mutations (Zhou et al. 2015), though not all subjects con-
clusively fulfilled the diagnostic criteria (Bao et al. 2013).
Figure 2. Genotype of Japanese ARVD/C
probands. (A) Pie graph showing the number
of probands who received the genetic test for
ARVD/C. (B) Each bar graph was color-coded
according to the proportion of truncating or
nontruncating mutations. Filled bar denotes
truncating mutation, white bar denotes
nontruncating mutation. Note that almost all
PKP2 mutations were truncating mutation,
whereas the other mutations were almost
nontruncating mutation.
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Notably, missense mutations in DSG2 in our cohort as
well as common polymorphisms in DSG2 in Japanese
controls were largely located in the extracellular domain
(amino acid residues 1-609). In contrast, missense muta-
tions in DSG2 in Caucasian probands are reportedly
located in the extracellular region, but its polymorphisms
are in the transmembrane and intracellular domain
(amino acid residues 610-1118), suggesting that only
mutations in the extracellular component may be malig-
nant (Kapplinger et al. 2011). But this seems not true in
Japanese, and thus DSG2 may be more vulnerable for the
occurrence of de novo variants in Japanese.
Genotype-specific risk stratification
Previous genotype-specific risk analyses among Cau-
casians have concluded that mutation status influences
relatives more strongly than it does probands because
even probands without mutations will develop symp-
toms in the near future. This finding implies that geno-
typic characterization may not be as helpful as it had
been thought to be in predicting outcomes in Cau-
casian probands. In Japanese probands, event-free sur-
vival is intergraded with age only among truncating
mutation carriers. PKP2-related early manifestation
(Ohno et al. 2013) has still been constantly observed
even though considerable numbers of DSG2 mutation
carriers were enrolled. Given that all lethal events
among young victims in our cohort occurred during
competitive exercise, exercise avoidance is the most
effective especially among young carriers not only for
preventing young carriers from disease development,
but from fatal events. The follow-up data of relatives
showed very few adverse events though, all three rela-
tives with lethal VAs (from different families) had
desmosomal mutations; interestingly, all three muta-
tions were nontruncating. The five relatives carrying
truncating mutations, in contrast, did not conclusively
fulfill the diagnostic criteria and did not experience
adverse outcomes at the moment. Whether truncating
mutation itself in relatives can affect either phenotype
or outcome must be further investigated in non-Cauca-
sian populations.
Influence of phenotype on outcome differs
according to mutation status
Preceding reports have strongly suggested the extrinsic
regulation of phenotype development (Nava et al. 2000;
Pilichou et al. 2009; James et al. 2013). In this study,
Figure 3. Survival curves and relative risk for
lethal ventricular arrhythmias in probands.
Kaplan–Meier survival curves for lethal
ventricular arrhythmias (VAs) were constructed
for groups sorted according to mutation
status: (A) truncating mutation carriers,
nontruncating mutation carriers, and mutation
negatives. Relative risk was calculated
according to age and mutation status
(B) compared to mutation negatives
(“absent”). Note the increased risk for lethal
VAs by 40s among probands with truncating
mutations.
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combined phenotype score did not differ between muta-
tion positives and negatives, nevertheless, this report did
clearly show the significant link between clinical outcomes
and genetic backgrounds. Desmosomal mutations, espe-
cially truncating ones in probands, per se played a harm-
ful role in outcome even when phenotype score was
relatively low. Consequently, probands other than trun-
cating mutation carriers could be further separated into
high-risk group with advanced phenotype and low-risk
group with mild phenotype.
Limitations
First, this study cohort contained insufficient numbers
of relatives with available clinical data, which prevented
us from describing phenotype spectrum, survival, and
disease course among family members. Second, pheno-
types were identified mainly by ECG and structural
findings, resulting in a lack of information about tissue
characteristics because most of the tissue samples were
obtained not from the right ventricle free wall but
rather from the interventricular septum. Third, variant
interpretation was based on a Japanese national data-
base derived from exome sequencing of 1208 individu-
als at most and genotyping data from 3248 individuals;
thus we could not completely dispel the possibility that
some preclinical ARVD/C probands, especially those
with missense variants, were incorporated among the
controls.
Conclusion
This survey revealed the divergent genetic and phenotypic
characteristics of ARVD/C in a mono-racial, non-Cauca-
sian population, leading to the mutation-dependent prog-
nosis which has never been concluded in Caucasian
probands. Japanese probands are most affected by DSG2
missense mutations followed by PKP2 truncating muta-
tions. Truncating mutations per se are responsible for the
early onset of lethal VAs regardless of phenotype severity.
Further investigation into the interaction between race
and genetic background on disease penetrance and out-
come is required.
Acknowledgments
We are grateful to all the patients and family members
whose participation enabled us to perform this research,
and also to all the institutes named below for their
cooperation in the nationwide survey for inherited
Figure 4. (A) Triggers of lethal arrhythmia in
probands with lethal ventricular arrhythmias.
Each bar is color-coded according to the
nature of the manifestation of lethal
ventricular arrhythmias. (B) Survivals associated
with different types and numbers of
mutations. The missense mutation carriers
shown in Figure 3A (blue line, nontruncating
mutation carriers) were separated according to
the number of mutation(s) harbored (yellow
and purple line).
648 ª 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Genetic Background and Prognosis of Japanese ARVD/C Probands Y. Wada et al.
arrhythmias: National Cerebral and Cardiovascular Cen-
ter, Osaka; Yamaguchi University Hospital, Yamaguchi;
Tenri Hospital, Nara; Oita University Hospital, Oita;
Tokyo Women’s Medical University Hospital, Tokyo;
Niigata University Hospital, Niigata; Kyoto University
Hospital, Kyoto; Keio University Hospital, Tokyo; Kochi
Medical School, Kochi; Ehime Prefectural Central
Hospital, Ehime; Nippon University Hospital, Tokyo;
Japan Red Cross Otsu Hospital, Shiga; Kitasato Univer-
sity Hospital, Kanagawa; Nagazaki University Hospital,
Nagasaki; Saitama Medical University Hospital, Saitama;
Seirei Mikatahara General Hospital, Shizuoka; Toyohashi
Heart Center, Aichi; Aichi Children’s Heart and Medical
Center, Aichi; Hikone Municipal Hospital, Shiga; Shi-
zuoka General Hospital, Shizuoka; Takeda Hospital,
Kyoto; Ehime University Hospital, Ehime; Osaka City
General Hospital, Osaka; Kusatsu General Hospital,
Shiga; Sapporo Medical University Hospital, Hokkaido;
Tsukuba University Hospital, Ibaraki; Tokyo Metropoli-
tan Bokutoh Hospital, Tokyo; Nagasaki Rosai Hospital,
Nagasaki; Higashihiroshima Medical Center, Hiroshima;
Kitaishikai Hospital, Ehime; Yujin-Yamazaki Hospital,
Shiga; Yokosuka Kyosai Hospital, Kanagawa; Yokohama
City Minato Red Cross Hospital, Kanagawa; Rumoi
Hospital, Hokkaido.
Disclosures
None.
Sources of Funding
This work was supported by a Grant-in-Aid for Scientific
Research from the Japan Society for the Promotion of
Science (M.H., 15H04818, S.O., 15K09689d), the Japan
Ministry of Health, Labour and Welfare (M.H., H24-033,
H26-040, H27-032), and Funds for Translational Research
from the Japan Circulation Society (M.H.).
References
Bao, J., J. Wang, Y. Yao, Y. Wang, X. Fan, K. Sun, et al. 2013.
Correlation of ventricular arrhythmias with genotype in
arrhythmogenic right ventricular cardiomyopathy. Circ.
Cardiovasc. Genet. 6:552–556.
Basso, C., B. Bauce, D. Corrado, and G. Thiene. 2012.
Pathophysiology of arrhythmogenic cardiomyopathy. Nat.
Rev. Cardiol. 9:223–233.
Gehmlich, K., P. Syrris, M. Reimann, A. Asimaki, E. Ehler, A.
Evans, et al. 2012. Molecular changes in the heart of a
severe case of arrhythmogenic right ventricular
Table 3. Clinical characteristics associated with mutation status at genotyping.
Truncating
mutation (+) N = 21
Nontruncating
mutation (+) N = 27
Mutation
negative N = 27 P value
Age at first evaluation, yrs 40  18 43  17 49  18 0.16
Age at genotyping, yrs 44  20 49  16 52  18 0.29
Age at final evaluation, yrs 46  20 51  16 54  19 0.34
Follow-up period, yrs 6.1  6.9 8.0  6.51 4.6  4.81 0.08
Male, n (%) 16 (76) 19 (70) 20 (74) 0.71
First manifestation
Lethal VAs, n (%) 14 (67) 15 (56) 14 (52) N.S.3
Nonlethal VAs, n (%) 2 (10) 5 (19) 5 (19) N.S.3
Heart failure, n (%) 2 (10) 2 (7) 1 (4) N.S.3
Family history, n (%) 1 (5) 1 (4) 0 N.S.3
Syncope, n (%) 2 (10) 2 (7) 5 (19) N.S.3
Others, (%) 0 1 (4) 2 (7) N.S.3
Major structural anomaly, (%) 14 (67) 18 (67) 19 (70) 0.78
Major repolarization anomaly, n (%) 19 (90)1,2 16 (59)1 12 (44)2 0.006
Major depolarization anomaly, n (%) 4 (19)1 13 (48)1 12 (44)1 0.09
Major ARVD/C-related VAs, n (%) 2 (10) 8 (30) 8 (30) 0.18
Phenotype score, pts 5.0  1.5 5.2  1.8 5.3  1.9 0.93
LVDD, mm 46  7 49  7 47  6 0.12
LVDS, mm 31  81 35  73 33  51 0.03
LVEF, % 58  141 46  151 55  12 0.03
ICD implantation at final evaluation, n (%) 9 (43) 16 (59) 16 (59) 0.42
Values are mean  SD or n/N (%). Abbreviations as in Table 1.
1P < 0.05 between annotated values.
2P < 0.01 between annotated values.
3P = N.S. between each category.
649ª 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Y. Wada et al. Genetic Background and Prognosis of Japanese ARVD/C Probands
cardiomyopathy caused by a desmoglein-2 null allele.
Cardiovasc. Pathol. 21:275–282.
Groeneweg, J. A., A. Bhonsale, C. A. James, A. S. te Riele, D.
Dooijes, C. Tichnell, et al. 2015. Clinical presentation, long-
term follow-up, and outcomes of 1001 arrhythmogenic right
ventricular dysplasia/cardiomyopathy patients and family
members. Circ. Cardiovasc. Genet. 8:437–446.
James, C. A., A. Bhonsale, C. Tichnell, B. Murray, S. D.
Russell, H. Tandri, et al. 2013. Exercise increases age-related
penetrance and arrhythmic risk in arrhythmogenic right
ventricular dysplasia/cardiomyopathy-associated desmosomal
mutation carriers. J. Am. Coll. Cardiol. 62:1290–1297.
Kapplinger, J. D., A. P. Landstrom, B. A. Salisbury, T. E.
Callis, G. D. Pollevick, D. J. Tester, et al. 2011.
Distinguishing arrhythmogenic right ventricular
cardiomyopathy/dysplasia- associated mutations from
background genetic noise. J. Am. Coll. Cardiol. 57:2317–2327.
Kato, K., N. Takahashi, Y. Fujii, A. Umehara, S. Nishiuchi, T.
Makiyama, et al. 2016. LMNA cardiomyopathy detected in
Japanese arrhythmogenic right ventricular cardiomyopathy
cohort. J. Cardiol. 68:346–351.
Marcus, F. I., W. J. McKenna, D. Sherrill, C. Basso, B. Bauce, D.
A. Bluemke, et al. 2010. Diagnosis of arrhythmogenic right
ventricular cardiomyopathy/dysplasia: proposed modification
of the task force criteria. Circulation 121:1533–1541.
Nava, A., B. Bauce, C. Basso, M. Muriago, A. Rampazzo, C.
Villanova, et al. 2000. Clinical profile and long-term follow-
up of 37 families with arrhythmogenic right
Figure 5. Phenotype scores associated with
different mutation statuses. (A) Bar charts
indicate the phenotype scores associated with
different mutation statuses and outcomes.
Note that higher phenotype score influenced
outcome in nontruncating mutation carriers
and mutation negatives, whereas phenotype
severity was independent of outcome in
truncating mutation carriers. Filled bars
represent lethal ventricular arrhythmia victims,
shaded bars represent intact individuals.
(B) Phenotype alteration was depicted by
plotting score at genotyping (X-axis) and after
follow-up (Y-axis). Value in each axis denotes
phenotype score derived from “the modified
2010 TFC.”
650 ª 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Genetic Background and Prognosis of Japanese ARVD/C Probands Y. Wada et al.
ventricular cardiomyopathy. J. Am. Coll. Cardiol.
36:2226–2233.
Ohno, S., I. Nagaoka, M. Fukuyama, H. Kimura, H. Itoh, T.
Makiyama, et al. 2013. Age-dependent clinical and genetic
characteristics in japanese patients with arrhythmogenic
right ventricular cardiomyopathy/dysplasia. Circ. J. 77:1534–
1542.
Pilichou, K., C. A. Remme, C. Basso, M. E. Campian, S. Rizzo,
P. Barnett, et al. 2009. Myocyte necrosis underlies
progressive myocardial dystrophy in mouse dsg2-related
arrhythmogenic right ventricular cardiomyopathy. J. Exp.
Med. 206:1787–1802.
Richards, S., N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster,
et al. 2015. Standards and guidelines for the interpretation
of sequence variants: a joint consensus recommendation of
the American college of medical genetics and genomics and
the association for molecular pathology. Genet. Med.
17:405–424.
Rigato, I., B. Bauce, A. Rampazzo, A. Zorzi, K. Pilichou, E.
Mazzotti, et al. 2013. Compound and digenic heterozygosity
predicts lifetime arrhythmic outcome and sudden cardiac
death in desmosomal gene-related arrhythmogenic right
ventricular cardiomyopathy. Circ. Cardiovasc. Genet. 6:533–
542.
Sen-Chowdhry, S., P. Syrris, and W. J. McKenna. 2005.
Genetics of right ventricular cardiomyopathy. J. Cardiovasc.
Electrophysiol. 16:927–935.
Sonoda, K., S. Ohno, S. Otuki, K. Kato, N. Yagihara, H.
Watanabe, et al. 2017. Quantitative analysis of PKP2 and
neighbouring genes in a patient with arrhythmogenic right
ventricular cardiomyopathy caused by heterozygous PKP2
deletion. Europace 19:644–650.
Te Riele, A. S., C. A. James, J. A. Groeneweg, A. C. Sawant, K.
Kammers, B. Murray, et al. 2016. Approach to family
screening in arrhythmogenic right ventricular dysplasia/
cardiomyopathy. Eur. Heart J. 37:755–763.
Thiene, G. 2015. The research venture in arrhythmogenic right
ventricular cardiomyopathy: a paradigm of translational
medicinedagger. Eur. Heart J. 36:837–846.
U. S. Census Bureau. 2013. The Asian alone population in the
United States: 2013. Current Population Survey, Annual
Social and Economic Supplement, 2013. Available at http://
www.census.gov/topics/population/race.html, last access
21 May 2016.
Zhou, X., M. Chen, H. Song, B. Wang, H. Chen, J. Wang,
et al. 2015. Comprehensive analysis of desmosomal gene
mutations in han Chinese patients with arrhythmogenic
right ventricular cardiomyopathy. Eur. J. Med. Genet.
58:258–265.
Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Appendix S1. Method: Interpretation for missense vari-
ant.
Table S1. Details of multiple mutations in Table 2.
Table S2. Repeat numbers in a microsatellite 15xGT and
an additional marker among 18 probands with
p.Asp494Ala (DSG2-D494A) variant.
Table S3. Clinical characteristics of 88 probands with
more than “possible” criteria by “the modified TFC”.
Figure S1. Odds for mutation possession in 88 probands
independent of genotypes.
Y. Wada et al. Genetic Background and Prognosis of Japanese ARVD/C Probands
651ª 2017 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
